Charles Schwab Investment Management Inc Aptinyx Inc. Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $7,600 - $51,600	-20,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$2.11 - $3.0 $42,200 - $60,000	20,000 New	20,000 $54,000
Q3 2021 Nov 16, 2021	SELL	$2.21 - $2.89 $38,873 - $50,835	-17,590 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.39 - $3.5 $170,445 - $249,606	-71,316 Reduced 80.22%	17,590 $50,000
Q4 2020 Feb 16, 2021	BUY	$2.93 - $4.3 $53,926 - $79,141	18,405 Added 26.11%	88,906 $308,000
Q2 2020 Aug 14, 2020	BUY	$1.99 - $4.4 $140,296 - $310,204	70,501 New	70,501 $294,000
Q3 2019 Nov 08, 2019	SELL	$3.0 - $4.08 $64,056 - $87,116	-21,352 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$2.95 - $4.38 $88,340 - $131,163	-29,946 Reduced 58.38%	21,352 $72,000
Q1 2019 May 14, 2019	BUY	$3.99 - $19.33 $3,247 - $15,734	814 Added 1.61%	51,298 $208,000
Q4 2018 Feb 14, 2019	SELL	$16.15 - $28.93 $5,813 - $10,414	-360 Reduced 0.71%	50,484 $836,000
Q3 2018 Nov 13, 2018	BUY	$20.21 - $31.85 $1.03 Million - $1.62 Million	50,844 New	50,844 $1.47 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.